Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges.
Therapeutics and clinical risk management · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
IBSantidepressantsfunctional gastrointestinal disordersgut-brain neuromodulatorsirritable bowel syndromeselective serotonin reuptake inhibitorsSelective serotonin reuptake inhibitorsAntidepressantsFunctional Gastrointestinal DisordersIbsGut-Brain Neuromodulators
Come citare questo studio
Alsfouk BA. (2026). Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges.. Therapeutics and clinical risk management. DOI: 10.2147/tcrm.s652958
Consulta la pubblicazione originale ↗